Orthopediatrics CORP 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
OrthoPediatrics Corp. announced a 15% revenue increase to $236.3 million in 2025, driven by core product performance and strategic acquisitions, despite continued operating losses.
NASDAQ
10-K: OrthoPediatrics Corp. Reports Fiscal Year 2024 Results, Highlights Strategic Growth and Acquisitions
OrthoPediatrics Corp. announces its financial results for the fiscal year ended December 31, 2024, showcasing revenue growth, strategic acquisitions, and a commitment to pediatric orthopedic care.
NASDAQ
OrthoPediatrics Corp.'s 10-K filing provides a detailed overview of its capital stock, including common and preferred shares, as well as information on stock options, warrants, dividends, registration rights, and anti-takeover provisions.